TIRUMALCHMThirumalai Chemicals Ltd.
Thirumalai Chemicals' ICRA rated limits fall to ₹1,330 crore
- Credit rating
- Chemicals - Organic

Thirumalai Chemicals (NSE: TIRUMALCHM) said in a filing on 17 Nov 2026 that ICRA has reaffirmed its long term BBB (Negative) rating on term loans, working capital and debentures, while cutting unallocated limits from ₹350 crore to ₹275 crore. Excluding the non-fund sub-limit, the total rated amount falls to ₹1,329.50 crore from ₹1,404.50 crore.
Key highlights
- Total rated amount: ₹1,329.50 crore, down from ₹1,404.50 crore
- Unallocated limits: ₹275 crore, down from ₹350 crore
- Interest coverage H1 FY2027: 0.7 times, against -0.3 times in FY2026
- Consolidated operating profit H1 FY2027: ₹71.2 crore, after earlier losses
The rating action in numbers
| Item | Detail |
|---|---|
| Agency | ICRA Limited |
| Term loan and working capital | [ICRA]BBB (Negative), reaffirmed; ₹445.00 crore and ₹334.50 crore, unchanged |
| Non-convertible debentures | [ICRA]BBB (Negative), reaffirmed; ₹100.00 crore, unchanged |
| Short term non-fund based facilities | [ICRA]A3+, reaffirmed; ₹175.00 crore, unchanged |
| Non-fund based sub-limit | [ICRA]A3+; ₹684.00 crore to ₹755.00 crore |
| Unallocated limits | [ICRA]BBB (Negative)/[ICRA]A3+; ₹350.00 crore to ₹275.00 crore |
| Letter dated | 17 Nov 2026, based on ICRA intimation dated 16 Nov 2026 |
Only the unallocated limits fall in the total
Of the rated lines, the amounts that move the total are the unallocated limits. The non-fund based sub-limit rises by ₹71.00 crore to ₹755.00 crore, but the filing labels it a sub-limit, and ICRA's total of ₹1,404.50 crore to ₹1,329.50 crore leaves it out. Excluding the sub-limit, the total is ₹75.00 crore lower, which is the cut in unallocated limits.
The term loan of ₹445.00 crore and the working capital facilities of ₹334.50 crore are both unchanged at [ICRA]BBB (Negative). ICRA's rating history shows the term loan and fund based limits moved from [ICRA]A+ (Stable) in FY2024 to [ICRA]BBB (Negative) in FY2027.
Profit has improved, but coverage remains under pressure
ICRA notes consolidated operating profit of ₹71.2 crore in H1 FY2027, against preceding losses, and attributes the improvement to PAN-OX spreads. The same table shows a consolidated loss after tax of ₹78.0 crore for H1 FY2027, against a loss of ₹167.9 crore in FY2026. ICRA's rationale refers to the Q2 FY2027 results announced on 05 Nov 2026.
Interest coverage is 0.7 times for H1 FY2027, against -0.3 times for FY2026. ICRA says coverage indicators remain under pressure and that sustained improvement in profitability remains a key monitorable.
Refinancing and the US project are the monitorables
ICRA names the timely refinancing of the loan for the US project as a key rating sensitivity. It says full commissioning and ramp-up of the US project, TCL Specialties LLC, will remain a key monitorable over the near to medium term, and that once stabilised the project is expected to improve product mix and geographical diversification.
ICRA expects overall liquidity to be supported by refinancing initiatives, other divestments and operational cash flows, and notes the refinancing options the company is considering to reduce pressure on coverage metrics.
What the rating action means for Thirumalai Chemicals' shareholders
The action changes the rated amounts on the company's borrowings and debentures. The total rated amount excluding the sub-limit falls by ₹75.00 crore, all in unallocated limits, while the non-fund sub-limit rises by ₹71.00 crore.
Not stated: the reason ICRA gave for the changes to the unallocated limits and the sub-limit, which refinancing options the company will pursue, whether the US project loan has been refinanced, and the company's own response. The filing gives no date for a next step.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
